What Is Anca Vasculitis Symptoms Diagnosis Treatment?

ANCA vasculitis is a rare autoimmune disease where your immune system attacks small blood vessels by mistake. It causes inflammation throughout the body, most often affecting the kidneys, lungs, and sinuses. The name comes from the abnormal ANCA antibodies found in the blood of most people with this condition. Treatment involves powerful medications to calm the immune system and prevent permanent organ damage.

What Exactly Is ANCA Vasculitis and How Does It Start?

ANCA stands for Anti-Neutrophil Cytoplasmic Antibody. These are proteins your immune system makes that target your own white blood cells. In ANCA vasculitis, these antibodies cause white blood cells to attack the walls of small blood vessels.

The inflammation that follows narrows or blocks the vessels. Tissues and organs downstream do not get enough blood. This can damage them permanently.

There are three main types of ANCA vasculitis. Microscopic polyangiitis (MPA) affects the kidneys and lungs. Granulomatosis with polyangiitis (GPA) also involves the sinuses and upper airways. Eosinophilic granulomatosis with polyangiitis (EGPA) includes asthma and high eosinophil counts.

Doctors do not know exactly what triggers it in each person. Some cases follow an infection or exposure to certain drugs. Genetics play a small role. Most people have no clear trigger at all.

About 1 in 50,000 people develop ANCA vasculitis each year in the United States. It can happen at any age but is most common in people over 50. It affects men and women about equally.

What Are the Most Common Symptoms of ANCA Vasculitis?

Symptoms vary widely because any organ with small blood vessels can be involved. But certain patterns are common.

Flu-like symptoms often appear first. Fatigue, fever, night sweats, joint pain, and weight loss lasting weeks or months are typical. Many people are told they have a stubborn virus before the real diagnosis emerges.

Kidney involvement is the most serious common feature. The National Institutes of Health reports that 70 to 80 percent of people with ANCA vasculitis develop kidney disease. Symptoms include foamy urine from protein loss, blood in the urine, and swelling in the legs or face. Without treatment, kidney failure can develop within weeks.

Lung symptoms are also frequent. Cough, shortness of breath, and coughing up blood happen because of inflammation in the air sacs. Some people develop nodules or cavities visible on a chest X-ray.

Sinus and ear symptoms are more common in GPA. Chronic sinus infections, bloody nasal discharge, ear pain, and hearing loss are typical. Collapse of the nasal bridge can happen in severe untreated cases.

Skin rashes appear in about 40 percent of people. These look like small red or purple spots called petechiae, often on the legs. Nerve damage can cause numbness, tingling, or weakness in the hands and feet.

How Is ANCA Vasculitis Diagnosed?

Diagnosis is often delayed. One study published in the journal Rheumatology found the average time from first symptom to diagnosis was 4 to 6 months. This matters because early treatment prevents organ damage.

The first step is a blood test for ANCA antibodies. Two types exist: PR3-ANCA and MPO-ANCA. PR3-ANCA is more common in GPA. MPO-ANCA is more common in MPA. A positive test strongly suggests the disease but is not definitive alone.

A tissue biopsy is the gold standard for confirmation. A small sample from an affected organ — usually the kidney or a skin lesion — is examined under a microscope. The biopsy shows inflamed blood vessels with a specific pattern.

Doctors also run tests to check organ function. Urinalysis looks for blood and protein. Blood tests measure creatinine to assess kidney function. Chest imaging checks for lung involvement.

No single test is perfect. About 10 to 15 percent of people with active ANCA vasculitis test negative for ANCA antibodies. These are called ANCA-negative vasculitis. Diagnosis then depends entirely on biopsy and clinical features.

What Does Treatment for ANCA Vasculitis Look Like?

Treatment has two phases. The first phase is remission induction. The goal is to stop the inflammation quickly. The second phase is maintenance. The goal is to keep the disease quiet with lower medication doses.

For severe disease involving the kidneys or lungs, the standard induction therapy is a combination of high-dose corticosteroids like prednisone plus a stronger immunosuppressant. Rituximab is the most common choice. Another option is cyclophosphamide. A 2020 clinical trial in the New England Journal of Medicine found rituximab and cyclophosphamide were equally effective for inducing remission, with about 70 percent of patients achieving it within 6 months.

Plasma exchange is sometimes used in the most severe cases with rapidly worsening kidney failure. The procedure filters ANCA antibodies out of the blood. Evidence from a 2020 trial called PEXIVAS showed it did not improve overall outcomes for most patients, so it is now used more selectively.

Once remission is achieved, maintenance therapy lasts 18 to 24 months or longer. Rituximab given every 6 months is the preferred maintenance drug. Low-dose prednisone may continue but doctors try to taper it off because of long-term side effects.

Some people with milder disease are treated with methotrexate or mycophenolate mofetil instead of rituximab. These are oral medications that also suppress the immune system.

What Are the Side Effects and Risks of Treatment?

Treatment is lifesaving but carries significant risks. The medications suppress the immune system broadly. This increases the risk of serious infections.

In the first year of treatment, about 20 to 30 percent of people develop a severe infection requiring hospitalization. Pneumonia is the most common. The CDC recommends that all patients receive pneumococcal and influenza vaccines before starting immunosuppression.

Corticosteroids have their own long-term problems. Weight gain, high blood pressure, diabetes, bone thinning, and cataracts are all linked to prolonged prednisone use. Doctors now aim to limit prednisone to the shortest time possible.

Rituximab can cause infusion reactions during the first dose. These include fever, chills, and rash. Rare but serious side effects include progressive multifocal leukoencephalopathy, a brain infection caused by the JC virus. The risk is estimated at 1 in 25,000 patients.

Cyclophosphamide carries a risk of bladder damage and bladder cancer with prolonged use. It can also reduce fertility. For this reason, it is now used mainly as a short-term induction therapy rather than long-term maintenance.

What Is the Long-Term Outlook for People With ANCA Vasculitis?

ANCA vasculitis is a chronic condition. It does not go away permanently. Most people experience relapses. Studies show that about 50 percent of patients will have at least one relapse within 5 years of initial treatment.

Relapse rates are higher in people with PR3-ANCA compared to MPO-ANCA. Smoking also increases relapse risk. Staying on maintenance therapy for at least 18 months reduces the chance of early relapse.

Kidney function is the main predictor of long-term outcomes. About 20 to 25 percent of people with kidney involvement eventually develop end-stage kidney disease requiring dialysis or transplant. Early diagnosis and treatment improve these numbers significantly.

Life expectancy is reduced compared to the general population. A large Swedish study published in 2021 found that people with ANCA vasculitis had a 2.5 times higher risk of death than matched controls. The leading causes of death were infections in the first year and cardiovascular disease later.

But these numbers are improving. Newer treatments and better management of side effects have improved survival substantially over the past 20 years. Many people live full lives with well-controlled disease.

Regular monitoring is essential. Blood tests every 1 to 3 months check kidney function and ANCA levels. A rising ANCA titer sometimes predicts a relapse, though not always. Doctors do not treat based on ANCA levels alone without symptoms.

What Are Common Misconceptions About ANCA Vasculitis?

One widespread myth is that ANCA vasculitis is contagious. It is not. You cannot catch it from someone else. It is an autoimmune disease, not an infection.

Another misconception is that a negative ANCA test rules out the disease. As noted earlier, up to 15 percent of people with confirmed disease test negative. Biopsy is still the standard when suspicion is high.

Some people believe that once symptoms improve, treatment can stop. This is dangerous. Stopping maintenance therapy early leads to relapse in most patients. Treatment is long-term even when you feel well.

There is also confusion about diet. Some online sources claim that special diets or supplements can cure ANCA vasculitis. As of 2026, there is no clinical evidence that any dietary change treats or reverses the disease. Good nutrition supports overall health but does not replace medication.

Frequently Asked Questions